The institutional sentiment decreased to 1.8 in Q2 2015. Its down 1.13, from 2.93 in 2015Q1. The ratio fall, as 12 funds sold all Vitae Pharmaceuticals Inc shares owned while 8 reduced positions. 14 funds bought stakes while 22 increased positions. They now own 13.29 million shares or 13.23% more from 11.74 million shares in 2015Q1.
Bvf Inc Il holds 4.08% of its portfolio in Vitae Pharmaceuticals Inc for 1.60 million shares. Nea Management Company Llc owns 2.61 million shares or 1.97% of their US portfolio. Moreover, Awm Investment Company Inc. has 1.78% invested in the company for 872,000 shares. The New York-based Ghost Tree Capital Llc has invested 1.44% in the stock. Perceptive Advisors Llc, a New York-based fund reported 150,000 shares.
Vitae Pharmaceuticals, Inc. is a biotechnology company. The company has a market cap of $178.05 million. The Firm is focused on discovering and developing small molecule drugs for diseases. It currently has negative earnings. It is engaged in developing a portfolio of product candidates through Contour, its structure drug discovery platform.
The post Vitae Pharmaceuticals Inc (VTAE) Profit Expected to Decrease appeared first on Octafinance.